Highest-materiality recent filing
ICU Medical shareholders approve simple majority voting, 25% special meeting right
Charter amendments eliminating supermajority and allowing 25%-owner special meetings effective May 15, 2026.
ICU Medical Q1 GAAP net income $30.1M vs loss a year ago; organic revenue up 1%
GAAP revenue $530.2M, down 12% YoY due to IV Solutions divestiture; non-GAAP organic revenue up 1%.
ICU Medical extends Executive Severance Plan term to Dec 31, 2028
Compensation Committee approved amendment extending plan expiration from Dec 31, 2025 to Dec 31, 2028.
ICU Medical Q4: revenue $540.7M (-14% YoY), GAAP loss $(0.64)/share, adj EPS $1.91
Revenue $540.7M vs $629.8M in Q4 2024, down 14.1% YoY.
ICU Medical Q3 revenue down 8.8% YoY; adjusted EPS improves to $2.03
Q3 revenue $537M vs $589M YoY; GAAP net loss narrowed to $3.4M from $33M.
ICU Medical Q2 revenue down 8% to $549M, but GAAP net income of $35.3M vs year-ago loss
Revenue $548.9M vs $596.5M YoY; GAAP gross margin improved to 38% from 35%.
ICU Medical shareholders approve stock plan amendment adding 2.15M shares
Shareholders approved amendment to 2011 Stock Incentive Plan, increasing share reserve by 2,150,000 to 8,515,510 shares.
ICU Medical Q1 revenue up 7% to $605M; adjusted EPS $1.72 vs $0.96
Revenue $604.7M, up 6.7% YoY from $566.7M.
ICU Medical Q4 2024 revenue up 7% to $629.8M; adj. EPS $2.11 vs $1.57
Revenue $629.8M (+7% YoY); GAAP gross margin improved to 36.1% from 29.2%.
ICU Medical Q3 2024 revenue up 6.5% to $589.1M; GAAP net loss $33M, adj EPS $1.59
Revenue $589.1M vs $553.3M YoY; GAAP gross margin improved to 34.8% from 33.2%.
ICU Medical appoints Daniel Woolson as President, effective Sept. 30, 2024
Daniel Woolson, 48, appointed President of ICU Medical, effective immediately on Sept. 30, 2024.
Revenue $596.5M up 8.6% YoY from $549.3M; GAAP gross margin 35% unchanged.
All seven director nominees elected: Vivek Jain, David C. Greenberg, Elisha W. Finney, David F. Hoffmeister, Donald M. Abbey, Laurie Hernandez, Kolleen T. Kennedy.
ICU Medical Q1 GAAP EPS $(1.63) loss, revenue flat at $566.7M
Revenue $566.7M, down slightly from $568.6M YoY; GAAP net loss $(39.5)M vs $(9.8)M.
ICU Medical director William Seeger resigns immediately ahead of Smiths board retirement
William Seeger resigned as director and Audit Committee member effective Feb. 28, 2024.
ICU Medical Q4 revenue up slightly but net loss widens; provides FY2024 guidance
Revenue $587.9M in Q4 2023, up 1.7% YoY from $578.0M.
ICU Medical reports Q3 revenue down 7.5% to $553.3M; GAAP EPS $0.30 vs loss, adjusted EPS $1.57
Revenue $553.3M vs $597.9M YoY (-7.5%), GAAP net income $7.2M ($0.30 diluted) vs loss of $13.2M.
ICU Medical amends bylaws to adopt universal proxy rules and exclusive forum provisions
Amendments effective Oct 30, 2023, address universal proxy rules under Rule 14a-19.
ICU Medical Q2 revenue $549.3M (-2% YoY); adjusted EPS $1.88 vs $1.37; narrows FY23 guidance
Revenue $549.3M vs $561.0M YoY; GAAP gross margin improved to 35% from 30%.
ICU Medical stockholders approve 2.2M share increase in 2011 Stock Incentive Plan
Share reserve increased by 2,186,000 to 6,365,510; plan extended through March 14, 2033.
ICU Medical Q1 revenue up 5% to $568.6M; GAAP loss narrows to $(0.41) from $(1.61)
Revenue $568.6M vs $543.1M YoY; GAAP gross margin 34% vs 31%.
ICU Medical Q4 2022 revenue $578M, GAAP net loss $15.5M, provides FY23 guidance
Revenue $578.0M vs $340.5M YoY; GAAP net loss $(15.5)M ($(0.65)/diluted) vs net income $19.9M ($0.91) in Q4 2021.
ICU Medical extends executive severance plan to Dec 31, 2025
Compensation Committee approved Second Amendment to Executive Severance Plan on Dec 30, 2022.
ICU Medical Q3 2022 revenue $597.9M; GAAP loss $(0.55)/share; adj EPS $1.75
Revenue $597.9M vs $336.1M YoY (+78%); GAAP net loss $(13.2)M ($(0.55)/diluted share).
ICU Medical Q2 revenue $561M; GAAP net loss $7.5M, adj EPS $1.37; updates FY guidance
Revenue $561.0M vs $321.7M YoY; GAAP net loss $(7.5M) vs income $28.4M.
ICU Medical shareholders elect all 9 director nominees and ratify auditor at 2022 annual meeting
All 9 director nominees elected; David F. Hoffmeister received most withheld votes (1,503,487) but was elected.
ICU Medical Q1 revenue $543M, GAAP net loss $38.1M, adjusted EPS $1.82
Revenue $543.1M, up 71% from $318.0M in Q1 2021.
ICU Medical amends CEO Vivek Jain's contract: base salary $775K, enhanced equity vesting
CEO Jain's base salary to $775,000 under amended employment agreement effective March 1, 2022 through March 2025.
ICU Medical files Smiths Medical FY2021 audited financials; operating profit down 88% to $16M
Smiths Medical revenue $1,153M in FY2021, flat vs $1,159M prior year.
ICU Medical Q4 2021 revenue up 6% to $340.5M; GAAP EPS drops to $0.91 from $1.21
Revenue $340.5M vs $320.5M YoY; GAAP net income $19.9M ($0.91 diluted EPS) vs $26.1M ($1.21).
ICU Medical CAO Kevin McGrody to retire effective March 18, 2022; CFO Bonnell to assume duties
CAO Kevin McGrody, 63, retiring effective March 18, 2022.
ICU Medical appoints William Seeger to Board; board expands to 9 members
William Seeger appointed to Board effective Feb 1, 2022; board expanded from 8 to 9.
ICU Medical completes acquisition of Smiths Medical for $1.85B cash + stock
Paid $1.85B cash and issued 2.5M shares of ICUI common stock; up to $100M additional contingent cash.
ICU Medical board: Swinney retires after 24 years; Kennedy appointed independent director
Robert Swinney retired from ICU Medical's board on Dec 31, 2021 after 24 years; no disagreement.
ICU Medical Q3 revenue $336.1M (+5.5% YoY); adj. EPS $2.07 vs $1.90
Revenue $336.1M, up from $318.6M in Q3 2020.
ICU Medical enters binding agreement to acquire Smiths Medical after put option exercised
Seller exercised put option on Sep 27, 2021, triggering binding purchase agreement for Smiths Medical.
ICU Medical to acquire Smiths Medical for $2.35B in cash and stock; expected close H1 2022
Total consideration: $1.85B cash, 2.5M ICUI shares (~$500M), plus up to $100M earn-out based on stock price.
ICU Medical wins arbitration; Pfizer not entitled to up to $225M earn-out from 2017 Hospira deal
Arbitrator ruled on August 7, 2021 that performance targets for HIS earn-out liability were not met.
ICU Medical Q2 revenue $321.7M (+6% YoY); adj. EPS $1.88 vs $1.65
GAAP net income $28.4M ($1.31 diluted EPS) vs $18.9M ($0.88) a year ago.
ICU Medical elects Laurie Hernandez to board, increasing size to eight
Board expanded to eight directors; Hernandez elected effective July 1, 2021.
On September 30, 2024, the Board of Directors of ICU Medical, Inc. (the “Company”) appointed Mr. Daniel Woolson, 48, as President of the Company, effective immediately.
On February 28, 2024, Mr. William Seeger notified the board of directors (the “Board”) of ICU Medical, Inc. (the “Company”) that he will retire from the board of directors of Smiths Group plc (“Smiths”) on May 31, 2024 and, in anticipation of his retirement, tendered his resignation from the Company Board and a member of the Audit and Compliance Committee of the Company Board as Smiths’ nominated director, effective immediately.
On February 16, 2022, Kevin McGrody, age 63, informed ICU Medical, Inc. (the “Company”) of his intention to retire as Chief Accounting Officer of the Company effective March 18, 2022.
appointed William Seeger to serve as a director of the Company, effective immediately.
On December 31, 2021, Robert S. Swinney notified ICU Medical, Inc. (the “Company”) of his resignation, effective December 31, 2021 from the Company’s Board of Directors (the “Board”) in accordance with the Board’s retirement policy after 24 years of service.
On December 31, 2021, the Board elected Ms. Kolleen Kennedy as a new director of the Company, effective December 31, 2021.
On July 1, 2021, the Board of Directors (the “Board”) of the Company elected Ms. Laurie Hernandez as the new director of the Company, effective July 1, 2021.
Max materiality 0.90 · Median 0.70 · Most common event earnings